Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Market Closed 06-12 16:00:00 EDT

2.46

-0.12

-4.84%

盘后2.48

+0.02+0.87%

19:50 EDT

High2.70	Low2.45	Vol644.75K
Open2.57	D1 Closing2.59	Amplitude9.67%
Mkt Cap21.18M	Tradable Cap20.66M	Total Shares8.61M
T/O1.65M	T/O Rate7.68%	Tradable Shares8.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":2.46,"timestamp":1781294400000,"preClose":2.585,"halted":0,"volume":644745,"hourTrading":{"tag":"盘后","latestPrice":2.4815,"preClose":2.46,"latestTime":"19:50 EDT","volume":10443,"amount":26506.2498,"timestamp":1781308232802,"change":0.0215,"changeRate":0.00874,"amplitude":0.04878},"delay":0,"changeRate":-0.04835589941972921,"floatShares":8396519,"shares":8611400,"eps":-4.37,"marketStatus":"Market Closed","change":-0.125,"latestTime":"06-12 16:00:00 EDT","open":2.57,"high":2.7,"low":2.45,"amount":1651350.036474,"amplitude":0.096712,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.37,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":2.585,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.585,"latestTime":"09:28 EDT","volume":8001,"amount":20747.1402684,"timestamp":1781270914099,"change":-0.025,"changeRate":-0.009671,"amplitude":0.083172},"postHourTrading":{"tag":"盘后","latestPrice":2.4815,"preClose":2.46,"latestTime":"19:50 EDT","volume":10443,"amount":26506.2498,"timestamp":1781308232802,"change":0.0215,"changeRate":0.00874,"amplitude":0.04878},"volumeRatio":1.9890316278691476,"impliedVol":1.2945,"impliedVolPercentile":0.664},"requestUrl":"/m/hq/s/ATOS","defaultTab":"news","newsList":[{"id":"2643821324","title":"Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2643821324","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643821324?lang=en_us&edition=fundamental","pubTime":"2026-06-13 05:31","pubTimestamp":1781299905,"startTime":"0","endTime":"0","summary":"Deal included 1,363,637 common shares or equivalents, Series A warrants, plus short-term Series B warrants for 1,363,637 shares each.Warrants become exercisable six months from issuance; Series A expires in 5.5 years; Series B expires in 2 years.Full warrant exercise could add about USD 12 million in gross proceeds.Net proceeds earmarked for clinical development, working capital, general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL8QWwwT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643132192","title":"Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2643132192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643132192?lang=en_us&edition=fundamental","pubTime":"2026-06-13 05:31","pubTimestamp":1781299869,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUAB6NSRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642369102","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2642369102","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642369102?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:47","pubTimestamp":1781200024,"startTime":"0","endTime":"0","summary":"Oracle  plans to raise about $40 billion via debt and equity issuances in fiscal 2027, including its previously announced $20 billion stock sale, the company said late Wednesday.Wedbush cut its price target for Oracle's shares to $240 from $275, citing the debt raise.Shares dropped 12%, with intraday trading volume rising to more than 41.4 million from the stock's daily average of about 26.1 million.Atossa Therapeutics  entered into a registered direct offering targeting gross proceeds of up to $16.5 million, the company said Thursday.Shares dropped 42%, with intraday trading volume rising to more than 1.1 million from the stock's daily average of 60,349.Oxford Industries'  shares slumped 18% after the clothing firm reported late Wednesday a fiscal Q2 sales outlook below analyst estimates, while Q1 adjusted earnings and revenue declined from a year ago.More than 958,000 shares of the company traded intraday compared with a daily average of about 347,000.Price: 178.43, Change: -22.84, P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OXM","LU1823568750.SGD","IE00BLSP4239.USD","LU0323591593.USD","LU0070302665.USD","LU0353189763.USD","LU1366192091.USD","IE00BBT3K403.USD","LU1046421795.USD","SG9999003800.SGD","LU1803068979.SGD","LU1435385759.SGD","LU1934455863.HKD","LU0082616367.USD","LU0985489474.SGD","LU0476273544.USD","LU0234572021.USD","LU0444971666.USD","LU0965509010.AUD","ORCS","IE00BMPRXN33.USD","LU1429558221.USD","LU2237957902.USD","LU1935043023.USD","LU0314106906.USD","LU0861579265.USD","LU2860962120.EUR","IE0004445239.USD","LU0289960550.SGD","LU0444973449.USD","LU0719512351.SGD","LU0109392836.USD","LU0965508806.USD","BK4543","LU2458330169.SGD","LU2236285917.USD","LU1989764748.USD","LU2360106780.USD","LU0553294199.USD","LU1935042991.SGD","LU1989772923.USD","LU1003077747.HKD","IE00BLSP4452.SGD","LU0068578508.USD","ORCX","LU1691799644.USD","LU1852331112.SGD","LU0056508442.USD","LU0198837287.USD","LU0433182093.SGD","LU0320765489.SGD","LU0889565833.HKD","SG9999001424.SGD","LU1642822529.SGD","LU0738911758.USD","LU0081259029.USD","IE00BN8TJ469.HKD","LU1720051108.HKD","IE00B3S45H60.SGD","LU2543165471.USD","LU0965509283.SGD","LU0234570918.USD","LU0965509101.SGD","LU0980610538.SGD","BK4534","LU0348723411.USD","LU1366333091.USD","LU1989764664.SGD","BK4097","LU0157215616.USD","BK4139","BK4516","LU2746668974.SGD","LU0648001328.SGD","LU0878866978.SGD","LU1037948897.HKD","LU2896262040.SGD","LU2054465674.USD","LU0353189680.USD","IE00B19Z3B42.SGD","LU1235294995.USD","LU1720051017.SGD","LU2087625088.SGD","IE00BMPRXQ63.HKD","ORCL","IE00B5949003.HKD","LU1935042488.USD","BK4581","BK4538","LU1037948541.HKD","LU0210536198.USD","BK4202","LU0130102774.USD","LU1201861249.SGD","LU2357305700.SGD","LU2746668461.USD","IE00B7SZLL34.SGD","IE00B775SV38.USD","BK4588","LU1035773651.USD","BK4528","LU1506573853.SGD","LU0545039389.USD","LU1815336760.USD","LU1934455277.USD","LU0208291251.USD","LU1989772840.SGD","LU1489326972.SGD","LU0256863811.USD","LU2108987350.USD","SG9999011175.SGD","LU0957808578.USD","LU1934455194.USD","LU1935043536.SGD","ATOS","LU0417517546.SGD","IE00BMPRXR70.SGD","LU0175139822.USD","LU0949170772.SGD","LU2237957811.SGD","IE0009356076.USD","BK4585","LU0661504455.SGD","LU2326559502.SGD","IE0002270589.USD","LU1069347547.HKD","LU2250418816.HKD","BK4533","LU1935042215.USD","LU1548497426.USD","ORCU","IE00B19Z3581.USD","LU2458330243.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284262","title":"Atossa Therapeutics Launches $16.5 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284262","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284262?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:39","pubTimestamp":1781181579,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics  has entered into a registered direct offering expected to raise up to $16.5 million in gross proceeds, the company said Thursday.The company said it will receive about $4.5 million upfront from the issuance of 1.36 million shares and accompanying warrants, with up to $12 million more possible if the warrants are fully exercised.The net proceeds will be used for clinical development of its product candidates, working capital and general corporate purposes, the company added.The closing of the offering is expected on or about Friday.Atossa Therapeutics shares were down more than 31% in premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","LENZ","BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281192","title":"Atossa Therapeutics issues Series A and B warrants for 1,363,638 shares in registered direct offering at $3.3 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281192","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281192?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:02","pubTimestamp":1781179321,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics launched a registered direct offering with 1,363,638 shares bundled with Series A warrants and short-term Series B warrants.Combined offering price USD 3.3 per share; warrants exercise at USD 4.4, exercisable six months from issuance.Series A warrants expire 5.5 years from issuance; Series B warrants expire in 2 years; closing expected June 12, 2026.Net proceeds expected at about USD 4.1 million; potential additional gross proceeds of about USD 12 million if warrants are exercised.No plan to list the Series Warrants on Nasdaq or any other trading venue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Dat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL49LXdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281965","title":"Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281965?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179209,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUABWXLTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638500793","title":"Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638500793?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:32","pubTimestamp":1779885124,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics announced two -endoxifen abstracts accepted for ASCO 2026, with presentations scheduled May 29 to June 2 in Chicago.New preclinical findings will be presented, supporting -endoxifen activity in models linked to endocrine-resistant ER-positive breast cancer.A trial-in-progress poster will outline the ongoing Phase 2 EVANGELINE study of -endoxifen with goserelin in premenopausal ER+/HER2- breast cancer.The study is designed to gauge early anti-tumor effect before surgery, with broader readouts intended to inform further development decisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 27, 2026, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL4gnYz2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638002325","title":"Atossa Therapeutics Announces Asco 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across Esr1 Mutations and Ongoing Evangeline Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638002325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638002325?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:30","pubTimestamp":1779885005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA7C6FTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637875850","title":"Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2637875850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637875850?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:45","pubTimestamp":1779309920,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics on May 20, 2026 announced acceptance of a review manuscript outlining how -endoxifen could modulate utrophin pathways as a potential treatment approach for Duchenne muscular dystrophy.No clinical study results were presented; the publication frames a mechanistic rationale and sets up future preclinical evaluation, with biomarker work intended to support later development decisions.The article argues -endoxifen may help create conditions that support utrophin-driven muscle stabilization and repair, potentially affecting key disease processes such as inflammation and fibrosis.The work builds on a 2025 Atossa-authored paper that proposed a broader therapeutic rationale for -endoxifen in Duchenne muscular dystrophy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL7rrHmY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633944468","title":"Atossa Therapeutics Inc  expected to post a loss of $1.03 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633944468","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633944468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:42","pubTimestamp":1778254928,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of $1.03 a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1X6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459412","title":"Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459412","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459412?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:53","pubTimestamp":1778244783,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Q1 net loss widens on higher legal and R&D expensesOverviewU.S. biopharma firm's Q1 net loss widened yr/yr on higher R&D and legal expensesCompany secured FDA Orphan Drug and Rare ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL1N41L0JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459918","title":"Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459918?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:46","pubTimestamp":1778244391,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics highlighted preclinical study results for -endoxifen in Duchenne muscular dystrophy that were already presented March 11, 2026 at MDA Clinical & Scientific Conference.Data indicated -endoxifen improved muscle function and body composition in dystrophic mouse models, supporting a move toward clinical testing.FDA granted Orphan Drug designation for -endoxifen in Duchenne muscular dystrophy in January 2026, strengthening regulatory positioning for a potential rare-disease development path.FDA also granted Rare Pediatric Disease designation for -endoxifen in McCune-Albright Syndrome in early May 2026, creating potential eligibility for a Priority Review Voucher upon approval of a qualifying marketing application.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL5rq01f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145964","title":"Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145964?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUAWKPK5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459644","title":"Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459644?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:45","pubTimestamp":1778244300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nPLX325B7E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456723","title":"Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456723?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:32","pubTimestamp":1778243538,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics posted a net loss of USD 9.6 million for the quarter ended March 31, 2026, while reporting no revenue.Operating expenses climbed 33.78% to USD 9.9 million, led by a 15% rise in R&D spending to USD 4.78 million.G&A costs rose 56% to USD 5.09 million, driven by higher legal fees tied to patent litigation and intellectual property matters.Cash and cash equivalents totaled USD 31.7 million at quarter-end as net cash used in operating activities widened to USD 9.58 million; management said existing resources likely will be insufficient to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL2PbXNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120455","title":"Atossa Therapeutics shareholders approve reverse stock split authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120455","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:02","pubTimestamp":1778241779,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics held its annual stockholder meeting on May 7, 2026.Stockholders backed an amendment to certificate of incorporation authorizing board to implement a reverse stock split, if it determines one is necessary or appropriate, at a ratio ranging from 2-for-1 to 20-for-1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7rZMFx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633448133","title":"Atossa says Phase 2 KARISMA trial shows Endoxifen cuts mammographic breast density 19.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633448133","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633448133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070835,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics flagged peer-reviewed publication of results from KARISMA Endoxifen trial in Journal of National Cancer Institute, with results already presented via publication.Phase 2 study in healthy premenopausal women showed low-dose oral endoxifen reduced mammographic breast density versus placebo, supporting its positioning as potential breast cancer risk-reduction option.Lower dose delivered meaningful effect with tolerability broadly similar to placebo, while higher dose drove more treatment-related discontinuations, shaping dose selection for future development.Program rationale centers on bypassing tamoxifen metabolism variability by dosing active metabolite directly, aiming to improve predictability and long-term acceptability in prevention setting.Next step remains clinical work to determine whether endoxifen lowers breast cancer incidence in higher-risk women, beyond biomarker changes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL2lhspQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633613311","title":"Atossa Therapeutics Announces Publication of Karisma Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2633613311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633613311?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:30","pubTimestamp":1778070645,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632395313","title":"BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2632395313","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632395313?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:34","pubTimestamp":1777898068,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright SyndromeMay 4 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS RECEIVES FD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA1QGBCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953990","title":"Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953990?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:32","pubTimestamp":1777897939,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics received FDA Rare Pediatric Disease designation for -endoxifen to treat McCune-Albright Syndrome in females.Designation could make company eligible for a Priority Review Voucher if a qualifying marketing application is approved.Disclosed Priority Review Voucher sales over past 18-24 months ranged from about $100 million to $205 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1djTrs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com;investors.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.4497},{"period":"1month","weight":-0.5233},{"period":"3month","weight":-0.509},{"period":"6month","weight":-0.8012},{"period":"1year","weight":-0.8099},{"period":"ytd","weight":-0.722}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.269844},{"month":2,"riseRate":0.5,"avgChangeRate":0.058135},{"month":3,"riseRate":0.428571,"avgChangeRate":0.091975},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.038564},{"month":5,"riseRate":0.357143,"avgChangeRate":-0.01529},{"month":6,"riseRate":0.571429,"avgChangeRate":0.081833},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}